Zometa, Aredia May Have Different Jaw Osteonecrosis Risk Profiles
Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested
Further study of jaw osteonecrosis risk may differentiate Novartis' bisphosphonates Zometa and Aredia, FDA Division of Oncology Drug Products Director Richard Pazdur suggested